Compare Shell PLC (SHEL) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Shell PLC vs TG Therapeutics Inc — how do they compare? Shell PLC trades at $100.18 (market cap $284.34B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Shell PLC is far larger — about 34.8× TG Therapeutics Inc's market cap, and Shell PLC pays a 3.12% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Shell PLC for 90 Days and TG Therapeutics Inc for 16 Days on average.
| SHEL | TGTX | |
|---|---|---|
Market Cap | $284.34B | $8.16B |
Volume | 9,097,469 | 1,735,121 |
Sector | Energy | Health |
52-Week High | $100.20 | $59.06 |
52-Week Low | $70.31 | $26.94 |
Typical Hold Time | 90 Days | 16 Days |
Enterprise Value | $326.04B | $8.37B |
Dividend Yield | 3.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Shell (SHEL) trades at $100.2, up 3.46% today, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and recent earnings beats in Q1 and Q2 2026. Fundamentally, the company maintains solid profitability with an 8.76% net margin and attractive valuation multiples, including a P/E of 11.08. Recent news highlights strategic expansions in LNG capacity and carbon capture projects, reinforcing long-term growth prospects.
The outlook for SHEL is positive, supported by analyst consensus favoring Buy ratings and a $102.53 price target. Key opportunities include LNG expansion and portfolio optimization, while risks involve energy price volatility and execution of large-scale projects. The stock presents a balanced risk-reward profile for investors seeking exposure to energy transition themes.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
